Veracyte Inc
$ 35.15
-2.33%
12 Feb - close price
- Market Cap 2,778,579,000 USD
- Current Price $ 35.15
- High / Low $ 36.09 / 34.17
- Stock P/E 95.00
- Book Value 15.91
- EPS 0.37
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 50.71
- 52 Week Low 22.61
About
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$47.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-02-20 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-08 | 2023-05-04 | 2023-02-22 |
| Reported EPS | 0.51 | 0.44 | 0.31 | 0.36 | 0.19 | 0.07 | -0.02 | -0.39 | -0.41 | -0.12 | -0.11 | -0.05 |
| Estimated EPS | 0.32 | 0.11 | -0.17 | 0.2571 | 0.03 | -0.02 | -0.16 | -0.09 | -0.15 | -0.15 | -0.13 | -0.15 |
| Surprise | 0.19 | 0.33 | 0.48 | 0.1029 | 0.16 | 0.09 | 0.14 | -0.3 | -0.26 | 0.03 | 0.02 | 0.1 |
| Surprise Percentage | 59.375% | 300% | 282.3529% | 40.0233% | 533.3333% | 450% | 87.5% | -333.3333% | -173.3333% | 20% | 15.3846% | 66.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCYT
2026-02-12 10:57:58
Thrivent Financial for Lutherans has acquired a new stake of 56,756 shares in Veracyte, Inc. (NASDAQ: VCYT) during the third quarter, valued at approximately $1.95 million. This purchase represents about 0.07% of the company's stock. Despite this institutional buying, company insiders have been net sellers, offloading 68,299 shares in the last 90 days.
2026-02-11 08:27:49
Allianz Asset Management GmbH increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 53.2% in Q3, now owning 134,097 shares worth approximately $4.6 million. Despite this, there has been accelerated insider selling by CFO Rebecca Chambers and Director Karin Eastham, totaling over $1.5 million in sales within a short period. Analyst ratings present a mixed view with a consensus "Hold" rating and an average price target of $46.14, although several firms issued "Buy" or "Strong-Buy" ratings while others maintained "Hold" or "Underweight."
2026-02-10 11:28:13
Federated Hermes Inc. significantly reduced its stake in Veracyte, Inc. by 96.1% in the third quarter, selling 52,039 shares and retaining 2,128 shares valued at $73,000. This divestment follows other institutional investors modifying their holdings, while company insiders, including the CEO and CFO, also sold a substantial number of shares recently. Despite insider and institutional selling, Wall Street analysts maintain a "Hold" consensus rating for Veracyte with a target price of $46.14.
2026-02-10 11:28:13
Principal Financial Group Inc. significantly increased its stake in Veracyte, Inc. by 667.9% in the third quarter, now owning 435,761 shares valued at approximately $14.96 million. Other institutional investors also adjusted their positions, while company insiders have been net sellers, disposing of 68,299 shares worth about $3.10 million in the last 90 days. Analyst ratings for Veracyte are mixed, with an average "Hold" rating and an average target price of $46.14.
2026-02-06 18:28:13
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 97.3% in the third quarter, now owning 139,109 shares valued at $4.78 million. This move is part of a broader institutional accumulation, despite recent insider selling by Director Karin Eastham and CFO Rebecca Chambers. While Veracyte beat Q3 EPS and revenue expectations, the stock trades below recent highs and holds a consensus "Hold" rating from analysts.
2026-02-05 20:59:26
Guggenheim reiterated a Buy rating on Veracyte (VCYT) with a $50.00 price target. Piper Sandler maintained a Hold rating on Sarepta Therapeutics (SRPT) with a $16.00 price target. Needham assigned a Buy rating to Viridian Therapeutics (VRDN) with a price target of $42.00, reflecting analyst consensus favoring a Strong Buy for VRDN.
